David Mateo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David Mateo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Margarita Torrente
Department of Psychology, Faculty of Educational Sciences and Psychology, Rovira i Virgili University, Tarragona, Spain
3 shared publications - Montse Marquès
Institute of Environmental Assessment and Water Research (IDAEA-CSIC)
2 shared publications - Cristian Cabrera
Laboratory of Toxicology and Environmental Health (LSTM), Center for Environmental, Food and Toxicological Technology (TECNATOX), Rovira i Virgili University, Reus, 43201, Spain; Department of Psychology, Faculty of Education Sciences and Psychology, Rovira i Virgili University, Tarragona, 43007, Spain; Institute Lerín Neurocognitive, Alzheimer and other Neurocognitive Disorders Association, Reus, Catalonia, 43205, Spain
1 shared publication - Eva Forcadell-Ferreres
Neurology, Hospital Verge de la Cinta de Tortosa, Tortosa, 43500, Spain
1 shared publication - José L. Domingo
Universitat Rovira i Virgili, Laboratory of Toxicology and Environmental Health, School of Medicine, Sant Llorenç 21, 43201 Reus, Catalonia, Spain
1 shared publication Luis Heredia
1 shared publication
Latest Publications
- Open Access
- 21 June 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 149, 108400
Shotgun metagenomic profiling of the gut microbiota in Parkinson's disease dementia and dementia with Lewy bodies
- 21 June 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 149, 108400
Open AccessShotgun metagenomic profiling of the gut microbiota in Parkinson's disease dementia and dementia with Lewy bodies
- Open Access
- 18 October 2023
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 195 (2) , e32959
Influence of gut microbiota on the development of most prevalent neurodegenerative dementias and the potential effect of probiotics in elderly: A scoping review
Dementia is one of today's greatest public health challenges. Its high socio‐economic impact and difficulties in diagnosis and treatment are of increasing concern to an aging world population. In recent years, the study of the relationship between gut microbiota and different neurocognitive disorders has gained a considerable interest. Several studies have reported associations between gut microbiota dysbiosis and some types of dementia. Probiotics have been suggested to restore dysbiosis and to improve neurocognitive symptomatology in these dementias. Based on these previous findings, the available scientific evidence on the gut microbiota in humans affected by the most prevalent dementias, as well as the probiotic trials conducted in these patients in recent years, have been here reviewed. Decreased concentrations of short‐chain fatty acids (SCFA) and other bacterial metabolites appear to play a major role in the onset of neurocognitive symptoms in Alzheimer disease (AD) and Parkinson disease dementia (PDD). Increased abundance of proinflammatory taxa could be closely related to the more severe clinical symptoms in both, as well as in Lewy Bodies dementia. Important lack of information was noted in Frontotemporal dementia behavioral variant. Moreover, geographical differences in the composition of the gut microbiota have been reported in AD. Some potential beneficial effects of probiotics in AD and PDD have been reported. However, due to the controversial results further investigations are clearly necessary.
- 18 October 2023
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 195 (2) , e32959
Open AccessInfluence of gut microbiota on the development of most prevalent neurodegenerative dementias and the potential effect of probiotics in elderly: A scoping review
Dementia is one of today's greatest public health challenges. Its high socio‐economic impact and difficulties in diagnosis and treatment are of increasing concern to an aging world population. In recent years, the study of the relationship between gut microbiota and different neurocognitive disorders has gained a considerable interest. Several studies have reported associations between gut microbiota dysbiosis and some types of dementia. Probiotics have been suggested to restore dysbiosis and to improve neurocognitive symptomatology in these dementias. Based on these previous findings, the available scientific evidence on the gut microbiota in humans affected by the most prevalent dementias, as well as the probiotic trials conducted in these patients in recent years, have been here reviewed. Decreased concentrations of short‐chain fatty acids (SCFA) and other bacterial metabolites appear to play a major role in the onset of neurocognitive symptoms in Alzheimer disease (AD) and Parkinson disease dementia (PDD). Increased abundance of proinflammatory taxa could be closely related to the more severe clinical symptoms in both, as well as in Lewy Bodies dementia. Important lack of information was noted in Frontotemporal dementia behavioral variant. Moreover, geographical differences in the composition of the gut microbiota have been reported in AD. Some potential beneficial effects of probiotics in AD and PDD have been reported. However, due to the controversial results further investigations are clearly necessary.
- Open Access
- 23 July 2023
- Published by Elsevier in Environmental Research
- Vol. 236 (Pt 1) , 116722
Metals linked with the most prevalent primary neurodegenerative dementias in the elderly: A narrative review
- 23 July 2023
- Published by Elsevier in Environmental Research
- Vol. 236 (Pt 1) , 116722
Open AccessMetals linked with the most prevalent primary neurodegenerative dementias in the elderly: A narrative review